Idexx Laboratories Inc /DE SEC filings IDXX
Idexx Laboratories Inc /DE has 1,005 filings in SEC EDGAR's recent list, going back to Feb 9, 2015. Its latest annual report, Form ARS, was filed on Mar 27, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 2, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 2, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Mar 27, 2026 | — |
| DEF 14A | Proxy statement | Mar 27, 2026 | Dec 31, 2025 |
| PRE 14A | Preliminary proxy statement | Mar 13, 2026 | Dec 31, 2025 |
| DEFA14A | Additional proxy material | Mar 28, 2025 | — |
| DEF 14A | Proxy statement | Mar 28, 2025 | Dec 31, 2024 |
| PRE 14A | Preliminary proxy statement | Mar 14, 2025 | Dec 31, 2024 |
| DEFA14A | Additional proxy material | Mar 27, 2024 | — |
| DEF 14A | Proxy statement | Mar 27, 2024 | Dec 31, 2023 |
| DEFA14A | Additional proxy material | Mar 31, 2023 | — |
| DEF 14A | Proxy statement | Mar 31, 2023 | — |
| DEFA14A | Additional proxy material | Mar 31, 2022 | — |
| DEF 14A | Proxy statement | Mar 31, 2022 | Dec 31, 2021 |
| DEFA14A | Additional proxy material | Mar 31, 2021 | — |
| DEF 14A | Proxy statement | Mar 31, 2021 | Dec 31, 2020 |
| DEFA14A | Additional proxy material | Mar 26, 2020 | — |
| DEF 14A | Proxy statement | Mar 26, 2020 | Dec 31, 2019 |
| DEFA14A | Additional proxy material | Mar 25, 2019 | — |
| DEF 14A | Proxy statement | Mar 25, 2019 | May 8, 2019 |
| DEFA14A | Additional proxy material | Mar 29, 2018 | — |
| DEF 14A | Proxy statement | Mar 29, 2018 | May 9, 2018 |
| DEFA14A | Additional proxy material | Mar 23, 2017 | — |
| DEF 14A | Proxy statement | Mar 23, 2017 | May 3, 2017 |
| DEF 14A | Proxy statement | Mar 24, 2016 | May 4, 2016 |
| DEFA14A | Additional proxy material | Mar 24, 2016 | — |
| DEFA14A | Additional proxy material | Mar 25, 2015 | — |
| DEF 14A | Proxy statement | Mar 25, 2015 | May 6, 2015 |
Showing 26 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- In Vitro & In Vivo Diagnostic Substances (SIC 2835)
- Listed as
- IDXX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Westbrook, ME
- SEC filer status
- Large accelerated filer
- SEC CIK
- 874716
Other In Vitro & In Vivo Diagnostic Substances companies
- Lantheus Holdings, Inc. LNTH
- Neogen Corp NEOG
- Celldex Therapeutics, Inc. CLDX
- Intellia Therapeutics, Inc. NTLA
- QuidelOrtho Corp QDEL
- Achieve Life Sciences, Inc. ACHV
- Myriad Genetics Inc MYGN
- Alpha Teknova, Inc. TKNO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.